Evidence map›Paper›PMID 39195638›Full record

ArticleToxics2024

Deriving a Continuous Point of Departure for Skin Sensitization Risk Assessment Using a Bayesian Network Model.

Fleur Tourneix, Leopold Carron, Lionel Jouffe, Sebastian Hoffmann, Nathalie Alépée

Abstract read
In one paragraph

Article in Toxics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fleur TourneixL'Oréal, Research & Innovation, 1Eugène Schueller, 93600 Aulnay-sous-Bois, France.
Leopold CarronL'Oréal, Research & Innovation, 1Eugène Schueller, 93600 Aulnay-sous-Bois, France.ORCID 0000-0003-1381-1390
Lionel JouffeBayesia S.A.S., Parc Cérès, Bâtiment N 21, rue Ferdinand Buisson, 53810 Changé, France.ORCID 0000-0003-0999-1835
Sebastian Hoffmannseh consulting + services, Stembergring 15, 33106 Paderborn, Germany.ORCID 0000-0002-3214-7678
Nathalie AlépéeL'Oréal, Research & Innovation, 1Eugène Schueller, 93600 Aulnay-sous-Bois, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulations of cosmetic ingredients and products have been the most advanced in embracing new approach methodologies (NAMs). Consequently, the cosmetic industry has assumed a forerunner role in the development and implementation of animal-free next-generation risk assessment (NGRA) that incorporates defined approaches (DAs) to assess the skin sensitization potency of ingredients. A Bayesian network DA predicting four potency categories (SkinSens-BN) was constructed against reference Local Lymph Node Assay data for a total of 297 substances, achieving a predictive performance similar to that of other DAs. With the aim of optimally informing risk assessment with a continuous point of departure (PoD), a weighted sum of the SkinSens-BN probabilities for four potency classes (non-, weak, moderate, and strong/extreme sensitizer) was calculated, using fixed weights based on associated LLNA EC3-values. The approach was promising, e.g., the derived PoDs for substances classified as non-sensitizers did not overlap with any others and 77% of PoDs were similar or more conservative than LLNA EC3. In addition, the predictions were assigned a level of confidence based on the probabilities to inform the evaluation of uncertainty in an NGRA context. In conclusion, the PoD derivation approach can substantially contribute to reliable skin sensitization NGRAs.

Indexed as

Bayesian networkdefined approachpoint of departurerisk assessmentskin sensitization

Identifiers

PMID39195638
PMCPMC11360414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.